Logo image of MASI

MASIMO CORP (MASI) Stock Fundamental Analysis

USA - NASDAQ:MASI - US5747951003 - Common Stock

146.05 USD
+3.51 (+2.46%)
Last: 10/2/2025, 8:16:26 PM
145.5 USD
-0.55 (-0.38%)
After Hours: 10/2/2025, 8:16:26 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to MASI. MASI was compared to 191 industry peers in the Health Care Equipment & Supplies industry. MASI has an average financial health and profitability rating. MASI has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

MASI had positive earnings in the past year.
MASI had a positive operating cash flow in the past year.
MASI had positive earnings in 4 of the past 5 years.
MASI had a positive operating cash flow in each of the past 5 years.
MASI Yearly Net Income VS EBIT VS OCF VS FCFMASI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

With a Return On Assets value of -19.11%, MASI perfoms like the industry average, outperforming 52.36% of the companies in the same industry.
The Return On Equity of MASI (-44.04%) is comparable to the rest of the industry.
MASI has a Return On Invested Capital of 5.19%. This is in the better half of the industry: MASI outperforms 76.96% of its industry peers.
MASI had an Average Return On Invested Capital over the past 3 years of 4.58%. This is below the industry average of 8.97%.
The last Return On Invested Capital (5.19%) for MASI is above the 3 year average (4.58%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -19.11%
ROE -44.04%
ROIC 5.19%
ROA(3y)-1.49%
ROA(5y)4.35%
ROE(3y)-4.1%
ROE(5y)3.92%
ROIC(3y)4.58%
ROIC(5y)8.17%
MASI Yearly ROA, ROE, ROICMASI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

MASI has a better Operating Margin (6.43%) than 73.30% of its industry peers.
MASI's Operating Margin has declined in the last couple of years.
MASI has a Gross Margin (52.76%) which is comparable to the rest of the industry.
MASI's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 6.43%
PM (TTM) N/A
GM 52.76%
OM growth 3Y-55.93%
OM growth 5Y-39.54%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.74%
GM growth 5Y-6.5%
MASI Yearly Profit, Operating, Gross MarginsMASI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

6

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so MASI is destroying value.
Compared to 1 year ago, MASI has more shares outstanding
Compared to 5 years ago, MASI has about the same amount of shares outstanding.
Compared to 1 year ago, MASI has an improved debt to assets ratio.
MASI Yearly Shares OutstandingMASI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
MASI Yearly Total Debt VS Total AssetsMASI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

MASI has an Altman-Z score of 5.57. This indicates that MASI is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.57, MASI belongs to the top of the industry, outperforming 82.72% of the companies in the same industry.
MASI has a debt to FCF ratio of 4.14. This is a neutral value as MASI would need 4.14 years to pay back of all of its debts.
The Debt to FCF ratio of MASI (4.14) is better than 82.20% of its industry peers.
A Debt/Equity ratio of 0.57 indicates that MASI is somewhat dependend on debt financing.
MASI has a worse Debt to Equity ratio (0.57) than 66.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.57
Debt/FCF 4.14
Altman-Z 5.57
ROIC/WACC0.63
WACC8.28%
MASI Yearly LT Debt VS Equity VS FCFMASI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 2.14 indicates that MASI has no problem at all paying its short term obligations.
The Current ratio of MASI (2.14) is worse than 60.21% of its industry peers.
A Quick Ratio of 1.61 indicates that MASI should not have too much problems paying its short term obligations.
The Quick ratio of MASI (1.61) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.14
Quick Ratio 1.61
MASI Yearly Current Assets VS Current LiabilitesMASI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 60.84% over the past year.
Measured over the past 5 years, MASI shows a small growth in Earnings Per Share. The EPS has been growing by 5.86% on average per year.
The Revenue has decreased by -8.36% in the past year.
Measured over the past years, MASI shows a quite strong growth in Revenue. The Revenue has been growing by 17.43% on average per year.
EPS 1Y (TTM)60.84%
EPS 3Y2.37%
EPS 5Y5.86%
EPS Q2Q%54.65%
Revenue 1Y (TTM)-8.36%
Revenue growth 3Y19.12%
Revenue growth 5Y17.43%
Sales Q2Q%-25.27%

3.2 Future

Based on estimates for the next years, MASI will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.14% on average per year.
Based on estimates for the next years, MASI will show a decrease in Revenue. The Revenue will decrease by -0.12% on average per year.
EPS Next Y27%
EPS Next 2Y17.47%
EPS Next 3Y15.6%
EPS Next 5Y12.14%
Revenue Next Year-27.11%
Revenue Next 2Y-11.36%
Revenue Next 3Y-5.25%
Revenue Next 5Y-0.12%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MASI Yearly Revenue VS EstimatesMASI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B
MASI Yearly EPS VS EstimatesMASI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2 4 6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 27.35, MASI can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of MASI indicates a somewhat cheap valuation: MASI is cheaper than 74.87% of the companies listed in the same industry.
MASI's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.86.
MASI is valuated rather expensively with a Price/Forward Earnings ratio of 24.73.
MASI's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. MASI is cheaper than 75.39% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of MASI to the average of the S&P500 Index (23.29), we can say MASI is valued inline with the index average.
Industry RankSector Rank
PE 27.35
Fwd PE 24.73
MASI Price Earnings VS Forward Price EarningsMASI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

MASI's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. MASI is cheaper than 67.54% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MASI indicates a somewhat cheap valuation: MASI is cheaper than 75.39% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 53.46
EV/EBITDA 44.04
MASI Per share dataMASI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

MASI's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as MASI's earnings are expected to grow with 15.60% in the coming years.
PEG (NY)1.01
PEG (5Y)4.67
EPS Next 2Y17.47%
EPS Next 3Y15.6%

More info and screens

0

5. Dividend

5.1 Amount

MASI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MASIMO CORP

NASDAQ:MASI (10/2/2025, 8:16:26 PM)

After market: 145.5 -0.55 (-0.38%)

146.05

+3.51 (+2.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-03 2025-11-03/amc
Inst Owners107.26%
Inst Owner Change5.52%
Ins Owners0.18%
Ins Owner Change2%
Market Cap7.93B
Analysts82.67
Price Target190.86 (30.68%)
Short Float %7.28%
Short Ratio5.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.44%
Min EPS beat(2)6.64%
Max EPS beat(2)10.25%
EPS beat(4)4
Avg EPS beat(4)11.67%
Min EPS beat(4)6.64%
Max EPS beat(4)14.9%
EPS beat(8)8
Avg EPS beat(8)11.28%
EPS beat(12)12
Avg EPS beat(12)9.75%
EPS beat(16)16
Avg EPS beat(16)8.76%
Revenue beat(2)0
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-1.35%
Max Revenue beat(2)-0.77%
Revenue beat(4)0
Avg Revenue beat(4)-1.08%
Min Revenue beat(4)-1.58%
Max Revenue beat(4)-0.59%
Revenue beat(8)0
Avg Revenue beat(8)-1.74%
Revenue beat(12)2
Avg Revenue beat(12)-1.66%
Revenue beat(16)5
Avg Revenue beat(16)-1.07%
PT rev (1m)0%
PT rev (3m)2.77%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.07%
EPS NY rev (1m)0%
EPS NY rev (3m)7.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.74%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.06%
Valuation
Industry RankSector Rank
PE 27.35
Fwd PE 24.73
P/S 4.29
P/FCF 53.46
P/OCF 44.92
P/B 7.61
P/tB 8.97
EV/EBITDA 44.04
EPS(TTM)5.34
EY3.66%
EPS(NY)5.91
Fwd EY4.04%
FCF(TTM)2.73
FCFY1.87%
OCF(TTM)3.25
OCFY2.23%
SpS34.02
BVpS19.2
TBVpS16.28
PEG (NY)1.01
PEG (5Y)4.67
Profitability
Industry RankSector Rank
ROA -19.11%
ROE -44.04%
ROCE 6.57%
ROIC 5.19%
ROICexc 5.66%
ROICexgc 6.25%
OM 6.43%
PM (TTM) N/A
GM 52.76%
FCFM 8.03%
ROA(3y)-1.49%
ROA(5y)4.35%
ROE(3y)-4.1%
ROE(5y)3.92%
ROIC(3y)4.58%
ROIC(5y)8.17%
ROICexc(3y)4.95%
ROICexc(5y)12.77%
ROICexgc(3y)9.27%
ROICexgc(5y)17.89%
ROCE(3y)5.8%
ROCE(5y)10.34%
ROICexcg growth 3Y-55.81%
ROICexcg growth 5Y-40.49%
ROICexc growth 3Y-58.97%
ROICexc growth 5Y-44.46%
OM growth 3Y-55.93%
OM growth 5Y-39.54%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.74%
GM growth 5Y-6.5%
F-Score6
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0.57
Debt/FCF 4.14
Debt/EBITDA 3.14
Cap/Depr 39.28%
Cap/Sales 1.53%
Interest Coverage 3.59
Cash Conversion 92.61%
Profit Quality N/A
Current Ratio 2.14
Quick Ratio 1.61
Altman-Z 5.57
F-Score6
WACC8.28%
ROIC/WACC0.63
Cap/Depr(3y)60.07%
Cap/Depr(5y)110.25%
Cap/Sales(3y)3.16%
Cap/Sales(5y)3.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.84%
EPS 3Y2.37%
EPS 5Y5.86%
EPS Q2Q%54.65%
EPS Next Y27%
EPS Next 2Y17.47%
EPS Next 3Y15.6%
EPS Next 5Y12.14%
Revenue 1Y (TTM)-8.36%
Revenue growth 3Y19.12%
Revenue growth 5Y17.43%
Sales Q2Q%-25.27%
Revenue Next Year-27.11%
Revenue Next 2Y-11.36%
Revenue Next 3Y-5.25%
Revenue Next 5Y-0.12%
EBIT growth 1Y-27.14%
EBIT growth 3Y-47.5%
EBIT growth 5Y-29%
EBIT Next Year42.43%
EBIT Next 3Y17.05%
EBIT Next 5Y13.83%
FCF growth 1Y624.38%
FCF growth 3Y-14.18%
FCF growth 5Y-0.52%
OCF growth 1Y535.25%
OCF growth 3Y-9.48%
OCF growth 5Y-2.39%